Manuscript title:

- 2 Relative expression of pro-inflammatory molecules in COVID-19 patients manifested disease
- 3 severities

1

8

- 4 **Running head:** Expression of pro-inflammatory molecules in COVID-19
- 5 **Authors:** Shireen Nigar ^{1#}, SM Tanjil Shah ^{2,3#}, Md. Ali Ahasan Setu ³, Sourav Dutta Dip ³,
- 6 Habiba Ibnat ³, M Touhidul Islam ⁴, Selina Akter ³, Iqbal Kabir Jahid ^{3,5}**, and M Anwar
- 7 Hossain ^{2,5,6}**
- ¹Department of Nutrition and Food Technology, Jashore University of Science and Technology,
- 10 Jashore-7408, Bangladesh
- ²Department of Microbiology, University of Dhaka, Dhaka-1000, Bangladesh
- ³ Department of Microbiology, Jashore University of Science and Technology, Jashore-7408,
- 13 Bangladesh
- ⁴ Consultant, Department of Cardiology, 250 Bedded General Hospital, Jashore
- ⁵ Genome Center, Jashore University of Science and Technology, Jashore-7408, Bangladesh
- ⁶ Vice-Chancellor, Jashore University of Science and Technology, Jashore-7408, Bangladesh
- 17 **Corresponding author:
- 18 Igbal Kabir Jahid, Head of the Department of Microbiology, Jahsore University of Science and
- Technology, Jahsore, Bangladesh. Phone: +8801709818178, Email: ikjahid mb@just.edu.bd

M Anwar Hossain, Director, Genome Center, Jahsore University of Science and Technology, Jahsore, Bangladesh. Vice-Chancellor, Jashore University of Science and Technology, Jashore-7408, Bangladesh. Phone: +8801715363753, Email: hossaina@du.ac.bd *These authors contributed equally to this study. Institution where the work has been performed: Jashore University of Science and Technology

Abstract

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

Aggressive immune response, due to over-expressed pro-inflammatory molecules, had been characterized in COVID-19 patients. Some of those mediators have a dual and opposite role on immune-systems to play behind differential disease severities. We investigated the expression of some cytokines and chemokines in COVID-19 patients in Bangladesh. We diagnosed the patients by detecting SARS-CoV-2 RNA in nasal swab samples by the real-time RT-PCR method. Thirty adult patients were preselected based on their disease severities and grouped into mild, moderate, and severe cases. Nine healthy volunteers participated in this study as control. Relative expression of nine cytokines/chemokine in total leukocytes was semi-quantified in SYBR green-based qRT-PCR. We performed statistical tests on transformed log data using SPSS 24.0. At the onset of symptoms (day-1), ACE2 (P < 0.05) and IL-6 (P > 0.05) were up-regulated in all COVID-19 groups, although expression levels did not significantly correlate with disease severities. However, expression of IL-6, MCP-1, MIP-1α, TNF-α, RANTES, and ACE2, on day-14, were positively correlated with disease severities. Relative viral load at day-1 showed no significant correlation with cytokine expression but had a significant positive correlation with RANTES and ACE2 expression on day-14 (P < 0.05). Male patients had a higher level of IL-6 than female patients on day-1 (P < 0.05). All COVID-19 patients showed up-regulated cytokines and chemokines on the day-14 compared to day-1 except TNF-α. Female patients had higher expression of ACE2 and IL-12 on day-14. Up-regulated cytokines/chemokines at the convalescent stage, especially IL-6, may target anti-cytokine therapy in post-COVID-19 patients' management.

Keywords: COVID-19, pro-inflammatory molecules, cytokines, chemokines, relative expression

58

Introduction

59

A novel coronavirus SARS-CoV-2 was identified in Wuhan, China, in December 2019 and has 60 lead to over 127 million cases and 2.79 million death worldwide as of March 31, 2021 [1]. 61 However, surprisingly in Bangladesh, these days recorded 0.61 million confirmed cases and only 62 9046 deaths [1]. COVID-19 related deaths are significantly lower in countries with lower quality 63 of life [2]. Although most SARS-CoV-2 patients demonstrate mild or moderate symptoms, it 64 could also lead to excessive, ineffective and exaggerated immune responses called cytokine 65 release syndrome (CRS). The clinical response shows acute respiratory distress syndrome 66 (ARDS), multiple organ failure, and ultimately death [3]. Several authors reported the role of 67 cytokines and chemokines as a double-edged sword. Higher levels of chemokines (such as MCP-68 69 1, MIP-1α, MIP-1β, RANTES, IP-10, and CCL3) and cytokines (such as IL-6, IL-8, IL-1b, TNF-α, IFNy, and GCSF, GMCSF) have reported for COVID-19 patients [3-6]. Several authors 70 have been reviewed the importance and function of these chemokines and cytokines [7-9] and 71 72 demonstrated the role of IL-6, TNF- α , IL-10, and IL-8 for disease severity. 73 The SARS-CoV-2 virus uses novel Metallo-carboxyl peptidase angiotensin receptor 2 (ACE2) to enter its human host cell [10, 11]. In spite of acting as the viral receptor, ACE2 protects against 74 lung injury by degrading vasoconstrictive and proapoptotic protein [12]. ACE2 expressed higher 75 in severe patients than mild and moderate [13]. The authors also found upregulation of several 76 77 interferons, cytokines, and immune-related genes for severe patients compared with mild and moderate patients. Biological sex variation influenced the severity of COVID-19 cases [14] as 78 reported in various studies; men are more likely to get severe forms of COVID-19 [15-17]. 79

Investigations will identify therapeutic strategies with anti-cytokine targeting overactive proinflammatory cytokines (TNF- α and IL-6). But the correct time for administrating anti-cytokine therapies needs to be recognized for personalized treatment of COVID-19 patients. Furthermore, the questions remained unanswered about the reasons for reduced severity and mortality in developing countries like Bangladesh, except for dissimilarity in cytokine/chemokine expression with recently reported data. We aimed to explore the relationships between disease severity and relative cytokine expression levels, the effect of biological sex in clinical presentation or viral load at the nasopharynx swap of COVID-19 patients.

Materials & Methods

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

Ethical permission and Sample collection:

The Ethical Review Committee of the Jashore University of Science and Technology approved this study (ERC no: ERC/FBST/JUST/2020-49). A total of 30 symptomatic COVID-19 patients were preselected, and patients were categorized into mild cases (n=10), moderate cases (n=10), and severe cases (n=10) of COVID-19 according to the World Health Organization Guidelines for Diagnosis and Treatment of COVID-19 infection [18]. We grouped patients with fever and slight upper respiratory tract symptoms as mild cases; patients with shortness of breathing, constant pain, or pressure in the chest as moderate cases; and patients with respiratory failure requiring intensive care units (ICU) as severe COVID-19 cases. We informed individual participants (COVID-19 patients) or their family members about the study protocol and took verbal consent. The demographic information of all participants enlisted in Table 1. Ten healthy individuals (gave their consent and participated in this study) were primarily selected, who were free from recent respiratory diseases, acute or chronic infectious diseases, and had no comorbidities. They maintained home-quarantine from the beginning of the COVID-19 outbreak in Bangladesh and tested negative for recent SARS-CoV-2 infection by using All Check COVID-19 IgG/IgM antibody assay (CALTH Inc., Republic of Korea). We exclude a sample from one volunteer in the final study due to the appearance of antibodies against SARS-CoV-2. All participants were BCG vaccinated within one month of birth (identified by the skin scar/mark on the left upper arm and their verbal confirmation). We have interviewed patients or their family members to collect demographic data and clinical history from all qualified participants. From hereafter, we refer to the healthy control as HC, mild COVID-19 cases as MIC, moderate COVID-19 cases as MOC, and severe COVID-19 cases as SC.

Quantification of SARS-CoV-2 viral load:

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

We performed detection of SARS-CoV-2 at the Genome Centre, Jashore University of Science and Technology, Jashore, Bangladesh. We extracted viral RNA from a 10 µL clinical specimen (nasal swab and throat swab) within 12 h of specimen collection using QuickExtractTM RNA extraction kit (Lucigen, Wisconsin, USA) following the manufacturer's instruction. Then, 10 µL of each viral RNA extract was amplified by one-step real-time quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) using Novel Coronavirus Nucleic Acid Diagnostic Kit (Sansure Biotech Inc., China). The kit detected n- and orf1b gene of SARS-CoV-2 and human RNase P gene as an internal control. In this study, samples with Ct values for both n- and orf1b genes of \leq 35.0 considered positive, that of >35.0 retested, and of >40.0 considered negative. We used equation $2^{-\Delta Ct}$ to estimate viral load, where $\Delta Ct = Ct_{\text{viral N gene}} - Ct_{\text{RNaseP}}^{[19]}$. We have translated all the data as $Log_{10}(1+2^{-\Delta Ct})$. Estimating cytokine and chemokine expression levels by qRT-PCR: We collected approximately 4 to 5 ml of peripheral blood samples, within 24-hours (day 1) of laboratory confirmation of SARS-CoV-2 in nasopharyngeal swabs, from thirty COVID-19 symptomatic and nine symptomatic patients. After 14 days, we collected blood samples from twenty patients with MIC (n=10) and MOC (n=10) symptoms from their residence while maintaining home quarantine. Three healthy volunteers (out of nine) tested SARS-CoV-2 positive during repeated sampling and let off from the study. So we had six samples from healthy volunteers on day-14. We could not collect blood samples from participants of the severe

COVID-19 cases as they were either decreased after 14 days of initial sample collection or

admitted into the intensive care unit (ICU) from whom we could not be allowed to collect the

blood. We extracted total mRNA from human leukocytes using 1 mL of whole blood from all study participants using the SV total RNA isolation system (Promega, USA), as per the manufacturer's instruction. According to the manufacturer's instruction, we prepared 20.0 µL cDNA from 8.0 uL of total mRNAs using the GoScriptTMReverse transcription system (Promega, USA). We diluted 20 µL cDNA into a final volume of 100.0 µL. We performed SYBR green intercalation qRT-PCR to detect the expression level of two pro-inflammatory cytokines (TNF- α and IL-6), two antiviral cytokines (IFN- γ and IL-12), four chemokines (MIP-1 α , RANTES, IP-10, and MCP-1), and ACE2. We used the primer sequences to detect these cytokines and chemokines from an earlier study ^[20]. The qRT-PCR was performed in OuantStudio TM 3 (Applied Biosystems, USA), using the following protocol: denaturation at 95 °C for 2 min followed by 40 cycles of 95 °C for 10 s, annealing for 30 s, and extension at 72 °C for 30 s. We analyzed the melting curve to determine the assay's specificity (60-95 °C, 0.05 °C/s). Annealing temperature varied for different primer pairs (such as ACE2: 53 °C; IL-6: 45 °C; TNF-α: 60 °C; IP-10: 45 °C; IFN-γ: 48 °C; MIP-1α: 58 °C; RANTES: 48 °C; MCP-1: 52 °C; IL-12: 50.5 °C; and β-actin: 60 °C). We performed each experiment in triplicate and Ct values with <10% variance considered for analyses only. In this essay, the human β -actin gene worked as the internal control. We accessed mRNA expression by relative quantification and calculated fold expression change by the $2^{\text{-ddCt}}$ method [21].

Statistical analysis:

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

The distribution of the fold expression change of mRNAs was skewed, so we log-transformed these data for further analyses. Results presented as median (interquartile range). Non-parametric tests such as the Kruskal-Walis test and Mann-Whitney U-Test were used to compare relative cytokine expression levels among the different groups where applicable. Spearman's rank correlation coefficient (r) analyzes the correlation between relative cytokine expression levels in total lymphocytes and the close viral load. Spearman rank correlation analyses the association between disease severity and cytokine expression levels. We performed statistical tests based on transformed log data using SPSS 24.0 for Windows (SPSS, Inc., Chicago, IL, USA) and GraphPad Prism 8.0 (GraphPad Software, USA) to construct all the figures logarithmic scales. If the two-tailed P values were <0.05, the test results were considered significant.

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

Result

Demographic and clinical characteristics of studied participants The demographic characteristics and clinical aspects of thirty COVID-19 patients and nine healthy volunteers listed in Table 1. Mean(±SD) age of MIC, MOC, and SC groups were estimated as $37.30(\pm 4.814)$, $40.20(\pm 4.69)$, and $58.40(\pm 3.361)$ years, respectively. HC groups' mean age was 23.89(±2.435) years. All MOC participants (n=10) and SC (n=10) suffered from shortness of breathing, but only two MIC reported such difficulties. All SC had respiratory failure and thus required ICU support. We recorded no death for mild and moderate groups but one death reported during the study period in the SC group. Relative expression levels of cytokine and chemokine in studied participants Fig 1 represented the comparison between different cytokine and chemokine expression levels on day-1 and day-14 among the study groups. Statistical analyses showed no significant difference (P > 0.05) among the four groups for any cytokine or chemokine on day-1, except for ACE2. The ACE2 expressed higher (P < 0.05) in the MIC group than HC group. The relative expression level of IL-6 was numerically higher in all COVID-19 groups than in the healthy control group, although this difference was non-significant (P > 0.05). To obtain changes of different cytokine and chemokine expression levels on day-14. Compared with the HC, the MIC group had increased (P < 0.05) expressions of IL-12 and IFNy and nonsignificant higher expression of IP-10 and MCP-1 at day-14. On the other hand, the MOC had statistically higher (P < 0.05) expressions of ACE2, IL-12, MCP-1, TNF- α , MIP-1 α , IL-6,

RANTES, IP-10, and IFN- γ on day-14 compared to the HC. Compared with the MIC group, the

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

MOC had numerically higher IL-6 levels and significantly higher expression (P < 0.05) of RANTES and ACE2. Correlation between disease severity and cytokine and chemokine expression level Spearman rank correlation analyses were performed to determine any correlations between disease severity and expression levels of cytokine and chemokine in COVID-19 patients, separately for both day-1 and day-14. Correlation coefficients (r) for all cytokine and chemokine (both day-1 and day-14) are shown in Fig 2A. Statistical analyses revealed that the relative expression levels of IL-6 (r= 0.609), TNF- α (r= 0.741), MIP-1 α (r= 0.607), MCP-1 (r= 0.486), RANTES (r = 0.623) and ACE2 (r = 0.845) on day-14 were positively correlated (P < 0.05) with disease severity (Fig 2B). However, no significant correlation between disease severity with any cytokine and chemokine was observed on day-1. But expression levels of IL-12 (r= 0.102), TNF- α (r= 0.110), IFN- γ (r= 0.166), IL-6 (r= 0.295), IP-10 (r= 0.210), and MIP-1 α (r= 0.128) were weakly positively correlated with severity on day-1. Correlation between viral load and cytokine and chemokine expression level Spearman rank correlation analyses were also done to determine any correlations between relative viral load and expression levels of cytokine and chemokine in COVID-19 patients. Correlation coefficients (r) for all cytokine and chemokine (both day 1 and day 14) are shown in Fig 3A. Expression levels of only TNF- α (r = 0.4469) had non-significant positive correlation (P > 0.05) with relative viral load at the onset of disease. Whereas IL-6 (r= -0.4182), RANTES (r = -0.2376), MIP-1 α (r = -0.2078), and MCP-1 (r = -0.3111) had non-significant weak negative correlation with relative viral load on day 1. However after 14 days, expression levels of RANTES (r = 0.4860) and ACE2 (r = 0.6471) had significant positive correlation (P < 0.05) with

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

the relative viral load (Fig 3B). Moreover, relative expression levels were non-significantly positively correlated with viral load for IL-12 (r = 0.3516), TNF- α (r = 0.4615), IL-6 (r = 0.4895), and MIP-1 α (r = 0.3538). Effect of gender on relative cytokine expression levels in COVID-19 patients To explore any effect of sex on cytokine and chemokine expression levels, we analyzed cytokine's relative expression levels of males and females on both day-1 and day-14 (Fig 4). Irrespective of sex, all cytokine and chemokine were up-regulated on day-14 than day-1, except for IL-6 and TNF- α . For male, IL-6 expression level was similar on both sampling times. TNF- α showed no significant difference in any comparison. The relative expression level of ACE2 and IL-12 were also identical in both gender on day-1. But both ACE2 and IL-12 were up-regulated (P < 0.05) in females on day-14. Additionally, we did not observe a significant difference in the relative expression level of IFN-y, RANTES, and IP-10 in males and females on both days. On the other hand, MCP-1 and MIP-1 α were up-regulated (P < 0.05) in females on day-1. But did not found any sex discrimination for expression of MCP-1 and MIP-1α on day-14. The relative expression level of IL-6 was higher (P < 0.05) in males on day-1 but did not vary significantly (P > 0.05) with genders on day-14. **Discussion** To our knowledge, this is the first study on cytokine/chemokine expression level in COVID-19 patients in Bangladesh. We observed up-regulation of ACE2 (P < 0.05) and IL-6 (P > 0.05) in MIC cases compared with HC on day-1 (Fig 1). Many natural, common ways such as taking

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

Vitamin C, Metformin, Vitamin B3, and Vitamin D can up-regulate ACE2 receptor [22]. Here in Bangladesh, doctors instructed COVID-19 patients to take Vitamin C and Vitamin B3 during their illnesses, increasing ACE2 expression. Although the virus uses ACE2 to enter into its host cell, up-regulation of the cellular ACE2 receptor would likely be anti-inflammatory and might have contributed to reduced mortality in COVID-19 patients. Pro-inflammatory cytokines such as IL-6, TNF- α , while up-regulated, trigger cytokine storms and ultimately lead to tissue damage and organ failure [23]. Although we observed a slightly increased expression of IL-6, we didn't observe TNF- α up-regulation at the onset of the disease (Fig 1). Like our study, normal TNF- α levels were reported in COVID-19 patients by Wan et al. [24]. However, elevated TNF-α levels in COVID-19 patients' sera were also reported recently [4, 25]. Recently some studies reported IL-6 as severity predictors of COVID-19 [26, 27]. In a meta-analysis including 1426 patients, complicated COVID-19 patients had higher IL-6 expression levels (>3 times) compared with other uncomplicated patients [28]. In our study, COVID-19 patients had no higher expression of either IFN-y or IL-12 than the HC group, which is indicative of the absence of elevated antiviral immune response at the onset of disease symptoms. Surprisingly, none of the cytokines and chemokines of ICU patients from the SC group shows significant differences compared with others. Zhang et al [29] found that ICU patients in China had higher levels of IL-2R, IL-6, IL8, IL10, and TNF- α compared with reference ranges of the normal man. In other studies from Finland, ICU patients had higher levels of IL-6, C-reactive protein, and procalcitonin compared with non-ICU patients [30]. Keddie et al [31] also noted similar findings. The authors demonstrated that CRP, IL-6, IL-10, and LDH significantly correlated with ARDS and respiratory support. In another study, Lev et al [32] also noted that IP-10 is associated with ICU patients and act as potential biomarkers. The combination of IL-6*IL-10 serum levels has shown a predictor of ICU

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

patients [33]. The less expression of most cytokines and chemokines might be probable reasons for less mortality rate (1.5%) of severe COVID-19 patients in Bangladesh. Moreover, in our study, the relative expression of cytokine and chemokines differs between 2 weeks. After 14 days, significant up-regulation of both antiviral cytokines (IFN-γ and IL-12) occurs in MIC and MOC. Although the antiviral immune response was not present in COVID-19 patients on the onset of disease, the antiviral immune response accelerated in those patients after 14 days. This up-regulation indicates enhanced host immunity to eliminate viral pathogens. Similar IL-12 up-regulation reported in both SARS-CoV [34] and SARS-CoV-2 infected patients [4, 35]. IL-12 has distinctive characteristics and has a vital role in positive and negative feedback [36]. On day 14, pro-inflammatory cytokine IL-6 was significantly higher in MOC but not in MIC cases. Whereas another pro-inflammatory cytokine, TNFα, was significantly up-regulated in all COVID-19 patients than HC. These findings suggest that pro-inflammatory cytokines had direct effects on the severity and complexity of COVID-19 disease. The anti-inflammatory cytokines levels got up-regulated compared to pro-inflammatory cytokines after 14 days. So, it might result in rapid recovery and reduced mortality in COVID-19 patients. On day-14, RANTES and ACE2 also up-regulated with the severity of COVID-19 disease. RANTES, a well-established chemoattractant, links innate and adaptive immune response. RANTES decreased significantly in SARS-CoV-2 infected persons in a recent study, where MIP-1α level was higher in ICU patients [4] We observed that the relative expression of some cytokines and chemokines varied among COVID-19 cases. Based on the samples' data on day 1, we could not establish any significant correlation between disease severity and relative cytokine expressions. But after 14 days, estimated expression levels of IL-6, TNF-α, MIP-1α, MCP-1, RANTES, and ACE2 correlated

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

with and differed significantly with COVID-19 severity groups (Fig 2). Several reviews highlighted the importance of cytokines and chemokines and demonstrated IL-1, IL-6, IL-8, IL-10, IL-2R, IL-18, MCP-1, and TNF- α for disease severity [8, 37, 38]. The cytokines and chemokines regulate the CD4 + T, CD8 +T, monocytes, neutrophils, and macrophages. However, we observed differences in the expressions between studies. Recent work by Oin et al [25] is also in accord with our observation, where COVID-19 severity was associated with increased levels of IL-6, IP-10, MCP-1, and MIP-1α. Although Costela-Ruiz et al [7] reported elevated TNF-α and its association with severity in COVID-19 patients, we didn't observe such differences. In another study, even the samples from nasopharyngeal swabs revealed the higher expression of IFN-γ and lowered expression of TGF-β1 and RANTES in symptomatic patients compared with negative patients [39]. But our studies demonstrated the higher expression of RANTES for MIC and MOC compared with HC. At the onset of disease, the relative viral load had no significant correlation with cytokines and chemokines' relative expression (Fig 3A). However, initial viral load positively correlated with expression levels of IL-12, TNF-α, IL-6, RANTES, MIP-1α, and ACE-2, after 14 days. A higher level of IL-6 and RANTES decreased CD8+ T cell and virus [40]. The results from our study agreed with that study. Although male tends to get more severe forms of COVID-19 diseases, we observed significant gender variation only for IL-6, MIP-1α, and MCP-1 on day 1 (Fig 4). Our observations of male patients who had up-regulated IL-6 than female patients at the beginning of the disease agreed with China's similar findings. The study reported a higher level of serum IL-6 male compared to female. Increased expression of IL-6 on day-1 might result in severe COVID-19 diseases in males. Interestingly both males and females had similar expression levels of pro-inflammatory cytokines (TNF-α, IL-6) after 14 days. On day-14, female patients had significant up-regulation

of ACE2 and IL-12. In response to vaccinations, women induced a robust immune response [41]. In a previous study, estrogens lead to cytokine up-regulation in mice treated with coronavirus. Estrogens had a protective role by suppressing the immune response's escalation phase [42]. As women are expressing more ACE2, therefore, less severity and death rate has been attributed in Bangladesh. A recent study showed that, compared with male patients, severe female patients had a greater IgG production level in weeks of the COVID-19 disease onset ^[6]. The protective role of IgG in female COVID-19 patients might be associated with the up-regulation of IL-12. There were a few limitations along with the small sample size in our study. We could not collect repeated blood samples after 14 days from severe patients admitted to ICU. We also estimated the relative expression levels of cytokines and chemokines instead of serum cytokine levels. However, live vaccines such as the bacillus Calmette-Guerin (BCG) are known to induce trained immunity (enhanced innate immune response to subsequent infections). COVID-19 cases reported being lower in countries with universal BCG vaccination programs (such as Bangladesh, Nepal, Bhutan, Japan) compared to those without the programs (such as the USA, Spain, Canada, Italy) [43]. We hypothesized that BCG vaccination might induce an immune response and reduce SARS-CoV-2 viremia and the severity of COVID-19 infections [44], and rapid recovery of SARS-CoV-2 infection in the country.

Conclusion

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

This study describes cytokine and chemokine expression among COVID-19 patients with different disease severity in a developing country, Bangladesh. We found that IL-6 could be targeted for anti-cytokine therapy here in Bangladesh. Although we could not prove any direct effect of BCG vaccinations on reduced severity of COVID-19, our data provide cytokine

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

expression levels in BCG vaccinated COVID-19 patients. Knowledge of the underlying mechanisms of differential expressions and associations of these cytokines with disease severity could help target the choice of therapies. Acknowledgments This work was supported by a research grant (UGC/JUST/2020-21/20) from the University Grant Commission, Bangladesh, through Jashore University of Science and Technology (JUST), Jashore. We thank all volunteers and COVID-19 patients who actively participated in this study. We also acknowledge the efforts of all doctors, nurses, health-care workers in fighting SARS-CoV-2. **Declaration of competing interest** The authors declare no completing interest to this work. **Authors' contribution statement** Shireen Nigar conceived the idea; SM Tanjil Shah, Ali Ahsan Setu, Sourav Datta Dip, Habiba Ibnat and Selina Akter performed the experiment; M Touhidul Islam collected and performed initial processing of samples; SM Tanjil Shah and Iqbal Kabir Jahid performed statistical analysis; Shireen Nigar and SM Tanjil Shah wrote the draft manuscript; Selina Akter, Iqbal Kabir Jahid and M Anwar Hossain finalize the manuscript; Shireen Nigar, Iqbal Kabir Jahid and M Anwar Hossain supervised the whole work and submitted the manuscript.

References:

340

361

1. Dong E, Du H and Gardner L, An interactive web-based dashboard to track COVID-19 in 341 342 real time. Lancet Infect Dis. 2020;**20**(5): 533-534. 2. Escobar LE, Molina-Cruz A and Barillas-Mury C, BCG vaccine protection from severe 343 344 coronavirus disease 2019 (COVID-19). Proc Natl Acad Sci. 2020;**117**(30): 17720-17726. 345 3. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS and Manson JJ, COVID-19: 346 consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229): 1033-1034. 347 4. Huang C, Wang Y, Li X, et al., Clinical features of patients infected with 2019 novel 348 coronavirus in Wuhan, China. Lancet. 2020;395(10223): 497-506. 349 350 5. Blanco-Melo D, Nilsson-Payant BE, Liu W-C, et al., Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;**181**(5): 1036-1045. e9. 351 352 6. Zeng F, Dai C, Cai P, et al., A comparison study of SARS □ CoV □ 2 IgG antibody 353 between male and female COVID□19 patients: a possible reason underlying different 354 outcome between sex. J Med Virol. 2020. Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, Ruiz C and Melguizo-Rodríguez 355 7. 356 L, SARS-CoV-2 infection: the role of cytokines in COVID-19 disease. Cytokine Growth 357 Factor Rev. 2020. 358 8. Mulchandani R, Lyngdoh T and Kakkar AK, Deciphering the COVID □ 19 cytokine 359 storm: Systematic review and meta □ analysis. Eur J Clin Invest. 2021;51(1): e13429. 9. Mauvais-Jarvis F, Aging, male sex, obesity, and metabolic inflammation create the 360

perfect storm for COVID-19. Diabetes. 2020;69(9): 1857-1863.

362 10. Turner AJ, Tipnis SR, Guy JL, Rice GI and Hooper NM, ACEH/ACE2 is a novel 363 mammalian metallocarboxypeptidase and a homologue of angiotensin-converting enzyme insensitive to ACE inhibitors. Can J Physiol Pharmacol. 2002;80(4): 346-353. 364 365 11. Li W, Moore MJ, Vasilieva N, et al., Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;**426**(6965): 450-454. 366 12. Gopallawa I and Uhal BD, Angiotensin-(1–7)/mas inhibits apoptosis in alveolar epithelial 367 cells through upregulation of MAP kinase phosphatase-2. Am J Physiol Lung Cell Mol 368 Physiol. 2016;**310**(3): L240-L248. 369 Jain R, Ramaswamy S, Harilal D, et al., Host transcriptomic profiling of COVID-19 370 13. patients with mild, moderate, and severe clinical outcomes. Comput Struct Biotechnol J. 371 2021;**19**: 153-160. 372 373 14. Wei X, Xiao Y-T, Wang J, et al., Sex differences in severity and mortality among 374 patients with COVID-19: evidence from pooled literature analysis and insights from 375 integrated bioinformatic analysis. arXiv preprint arXiv:2003.13547, 2020. 376 15. Yang X, Yu Y, Xu J, et al., Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, 377 observational study. Lancet Respir Med. 2020;8(5). 378 379 16. Abate BB, Kassie AM, Kassaw MW, Aragie TG and Masresha SA, Sex difference in coronavirus disease (COVID-19): a systematic review and meta-analysis. BMJ open. 380 2020;**10**(10): e040129. 381 17. Liu T, Balzano-Nogueira L, Lleo A and Conesa A, Transcriptional differences for 382 COVID-19 Disease Map genes between males and females indicate a different basal 383

immunophenotype relevant to the disease. Genes. 2020;**11**(12): 1447.

384

- 385 18. Jin Y-H, Cai L, Cheng Z-S, et al., A rapid advice guideline for the diagnosis and
- treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard
- version). Mil Med Res. 2020;**7**(1): 4.
- 388 19. Chi Y, Ge Y, Wu B, et al., Serum Cytokine and Chemokine Profile in Relation to the
- Severity of Coronavirus Disease 2019 in China. J Infect Dis. 2020;222(5): 746-754.
- 390 20. Law HK, Cheung CY, Ng HY, et al., Chemokine up-regulation in sars-coronavirus—
- infected, monocyte-derived human dendritic cells. Blood. 2005;**106**(7): 2366-2374.
- 21. Livak KJ and Schmittgen TD, Analysis of relative gene expression data using real-time
- quantitative PCR and the $2-\Delta\Delta$ CT method. Methods. 2001;**25**(4): 402-408.
- 394 22. McLachlan CS, The angiotensin-converting enzyme 2 (ACE2) receptor in the prevention
- and treatment of COVID-19 are distinctly different paradigms. Clin Hypertens.
- 396 2020;**26**(1): 1-3.
- 397 23. Tanaka T, Narazaki M and Kishimoto T, Immunotherapeutic implications of IL-6
- blockade for cytokine storm. Immunotherapy. 2016;8(8): 959-970.
- 399 24. Wan S, Yi Q, Fan S, et al., Characteristics of lymphocyte subsets and cytokines in
- peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia
- 401 (NCP). MedRxiv, 2020.
- 402 25. Qin C, Zhou L, Hu Z, et al., Dysregulation of immune response in patients with
- 403 coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;**71**(15): 762-768.
- 404 26. Han H, Ma Q, Li C, et al., Profiling serum cytokines in COVID-19 patients reveals IL-6
- and IL-10 are disease severity predictors. Emerg Microbes Infect. 2020;9(1): 1123-1130.
- Liu Y, Zhang C, Huang F, et al., Elevated plasma level of selective cytokines in COVID-
- 407 19 patients reflect viral load and lung injury. Natl Sci Rev. 2020.

- 408 28. Aziz M, Fatima R and Assaly R, Elevated interleukin ☐ 6 and severe COVID ☐ 19: A
- 409 meta □ analysis. J Med Virol. 2020.
- 29. Zhang D, Zhou X, Yan S, et al., Correlation between cytokines and coagulation-related
- parameters in patients with coronavirus disease 2019 admitted to ICU. Clinica Chimica
- 412 Acta. 2020;**510**: 47-53.
- Broman N, Rantasärkkä K, Feuth T, et al., IL-6 and other biomarkers as predictors of
- severity in COVID-19. Ann Med. 2020;1-5.
- 415 31. Keddie S, Ziff O, Chou MK, et al., Laboratory biomarkers associated with COVID-19
- severity and management. Clin Immunol. 2020;**221**: 108614.
- 417 32. Lev S, Gottesman T, Sahaf Levin G, et al., Observational cohort study of IP-10's
- 418 potential as a biomarker to aid in inflammation regulation within a clinical decision
- support protocol for patients with severe COVID-19. Plos one. 2021;**16**(1): e0245296.
- 420 33. Nagant C, Ponthieux F, Smet J, et al., A score combining early detection of cytokines
- accurately predicts COVID-19 severity and intensive care unit transfer. Int J Infect Dis.
- 422 2020;**101**: 342-345.
- Wong C, Lam C, Wu A, et al., Plasma inflammatory cytokines and chemokines in severe
- acute respiratory syndrome. Clin Exp Immunol. 2004;**136**(1): 95-103.
- 425 35. Chen N, Zhou M, Dong X, et al., Epidemiological and clinical characteristics of 99 cases
- of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet.
- 427 2020;**395**(10223): 507-513.
- 428 36. Jones LL and Vignali DA, Molecular interactions within the IL-6/IL-12 cytokine/receptor
- superfamily. Immunol Res. 2011;**51**(1): 5.

430 37. Noroozi R, Branicki W, Pyrc K, et al., Altered cytokine levels and immune responses in 431 patients with SARS-CoV-2 infection and related conditions. Cytokine. 2020;155143. Bindoli S, Felicetti M, Sfriso P and Doria A, The amount of cytokine-release defines 432 38. 433 different shades of Sars-Cov2 infection. Exp Biol Med. 2020;245(11): 970-976. 39. Villalba MCM, Ramírez OV, Jiménez MM, et al., Interferon gamma, TGF-β1 and 434 435 RANTES expression in upper airway samples from SARS-CoV-2 infected patients. Clin 436 Immunol. 2020;**220**: 108576. 437 40. Patterson BK, Seethamraju H, Dhody K, et al., Disruption of the CCL5/RANTES-CCR5 438 pathway restores immune homeostasis and reduces plasma viral load in critical COVID-19. MedRxiv, 2020. 439 Lotter H and Altfeld M. Sex differences in immunity. in *Seminars in Immunopathology*. 440 41. 2019. Springer. 441 442 42. Taghizadeh-Hesary F and Akbari H, The powerful immune system against powerful 443 COVID-19: A hypothesis. Med Hypotheses. 2020;109762. 444 43. Sharma AR, Batra G, Kumar M, et al., BCG as a game-changer to prevent the infection and severity of COVID-19 pandemic. Allergol Immunopathol. 2020. 445 44. Curtis N, Sparrow A, Ghebreyesus TA and Netea MG, Considering BCG vaccination to 446 447 reduce the impact of COVID-19. Lancet. 2020;**395**(10236): 1545-1546.

448

449

Figure legends

Figure 1: Relative expression levels of cytokine and chemokine in healthy control and COVID-19 infected symptomatic patients (mild COVID-19 cases, moderate COVID-19 cases). ● = Healthy Control; ■ = Mild COVID-19 cases; ▲ = Moderate COVID-19 cases; and ▼ = Severe COVID-19 cases. Each RT-PCR was done in triplicate and data those vary <10% were taken for analyses. Because of this, number of samples varies for different cytokine and chemokine. Data are expressed as median with interquartile range (IQR). Separate analyses were performed for day 1 and day 14. For any cytokine, different letters in different column indicates significant differences (P < 0.05). Abbreviations: NA, not available (severe COVID-19 cases data on day 14); IL, interleukin; IFN, interferon; TNF, tumor necrosis factor; RANTES, Regulated upon activation, normal T cell expressed and secreted; IP-10, interferon-inducible protein of 10 kDa; MIP, macrophage inflammatory protein; MCP, monocyte chemotactic protein; and ACE, angiotensin converting enzyme.

Figure 2: Correlation between disease severity and relative expression levels of cytokine and chemokines. (A). Spearman rank correlation analyses between disease severity and cytokine expression levels were done, and correlation coefficient (r) values of IL-12, IFN- γ , TNF- α , IL-6, RANTES, IP-10, MIP-1 α , MCP-1, and ACE2 on day 1 and day 14 are plotted. * P < 0.05, **P < 0.01, ***P < 0.001. (B). Correlation between disease severity and relative expression levels of IL-6, TNF- α , RANTES, MIP-1 α , MCP-1, and ACE2 after 14 days are plotted. Here in the X axis, 1= healthy volunteer, 2= mild COVID-19 cases, and 3= moderate COVID-19 cases. Abbreviations: IL, interleukin; IFN, interferon; TNF, tumor necrosis factor; RANTES, Regulated upon activation, normal T cell expressed and secreted; IP-10, interferon-inducible protein of 10 kDa; MIP, macrophage inflammatory protein; MCP, monocyte chemotactic protein; and ACE, angiotensin converting enzyme.


Figure 3: Correlation between relative viral load and relative expression levels of cytokine and chemokines in COVID-19 patients. (A). Spearman rank correlation analyses between relative viral load and cytokine expression levels were done, and correlation coefficient (r) values of IL-12, IFN- γ , TNF- α , IL-6, RANTES, IP-10, MIP-1 α , MCP-1, and ACE2 on day 1 and day 14 are plotted. * P < 0.05, **P < 0.01. (B). Correlation between relative viral load and expression levels of IL-12, TNF- α , IL-6, RANTES, MIP-1 α , and ACE2 after 14 days are plotted. Abbreviations: IL, interleukin; IFN, interferon; TNF, tumor necrosis factor; RANTES, Regulated upon activation, normal T cell expressed and secreted; IP-10, interferon-inducible protein of 10 kDa; MIP, macrophage inflammatory protein; MCP, monocyte chemotactic protein; and ACE, angiotensin converting enzyme.


Figure 4: Relative expression levels of cytokine and chemokine in male and female COVID-19 patients. Here, = male and = female COVID-19 infected patients. Each RT-PCR was done in triplicate and data those vary <10% were taken for analyses. Because of this number of samples varies for different cytokine and chemokine. Data are expressed as median with interquartile range (IQR). Separate analyses were performed for day 1 and day 14. For any cytokine, different letters in different column indicates significant differences (P < 0.05). Abbreviations: IL, interleukin; IFN, interferon; TNF, tumor necrosis factor; RANTES, Regulated upon activation, normal T cell expressed and secreted; IP-10, interferon-inducible protein of 10 kDa; MIP, macrophage inflammatory protein; MCP, monocyte chemotactic protein; and ACE, angiotensin converting enzyme.


Table 1. Demographic and clinical characteristics of studied participants.

Characteristics	НС	MIC	MOC	SC
	(n=9)	(n=10)	(n=10)	(n=10)
Men	5 (55.55%)	6 (60%)	8 (80%)	6 (60%)
Women	4 (44.45%)	4 (40%)	2 (20%)	4 (40%)
Age [mean(±SD)] years	23.89(±2.435	37.30(±4.814)	40.20(±4.69)	58.40(±3.3
)			61)
Fever (temperature >37 °C)	0	8 (80%)	10 (100%)	9 (90%)
Cough	0	4 (40%)	8 (80%)	8 (80%)
Headache	0	5 (50%)	6 (60%)	6 (60%)
Malaise	0	2 (20%)	10 (100%)	7 (70%)
Myalgia	0	2 (20%)	5 (50%)	3 (30%)
Loss of taste or odor	0	0	6 (60%)	4 (40%)
Shortness of breathing	0	2 (20%)	7 (70%)	10 (100%)
Constant pain or pressure in chest	0	3 (30%)	5 (50%)	5 (50%)
SPO ₂ at rest $\leq 94\%$	0	0	0	6 (60%)
Respiratory failure requiring	0	0	0	10 (100%)
intensive care unit treatment				
Diabetes	0	0	0	4 (40%)
Hypertension	0	0	1 (10%)	6 (60%)

Abbreviations: HC; Healthy control, MIC; mild COVID-19 cases, MOC; moderate COVID-19 cases, SC; severe COVID-19 cases.







A

